



CÔNG TY CỔ PHẦN
DƯỢC PHẨM CPC1 HÀ NỘI
HA NOI CPC1
PHARMACEUTICAL JSC

CỘNG HOÀ XÃ HỘI CHỦ NGHĨA VIỆT NAM
Độc lập – Tự do – Hạnh phúc
SOCIALIST REPUBLIC OF VIETNAM
Independence – Freedom – Happiness

Số/No. 364 /2025/TB-CPC1HN

Hà Nội, ngày 14 tháng 8 năm 2025
Hanoi, August 14, 2025

CÔNG BỐ THÔNG TIN ĐỊNH KỲ BÁO CÁO TÀI CHÍNH
INFORMATION DISCLOSURE FINANCIAL STATEMENT

Kính gửi/To.

- Ủy ban chứng khoán nhà nước/ *The State Securities Commission*;
- Sở Giao dịch Chứng khoán Hà Nội/ *Hanoi Stock Exchange* ;

Thực hiện quy định tại khoản 3 Điều 14 Thông tư số 96/2020/TT-BTC ngày 16/11/2020 của Bộ Tài chính hướng dẫn công bố thông tin trên thị trường chứng khoán, Công ty Cổ phần Dược phẩm CPC1 Hà Nội thực hiện công bố thông tin báo cáo tài chính (BCTC) bán niên năm 2025 với Sở Giao dịch Chứng khoán Hà Nội như sau:

Pursuant to Clause 3, Article 14 of Circular No. 96/2020/TT-BTC dated November 16, 2020 of the Ministry of Finance guiding information disclosure on the securities market, Ha Noi CPC1 Pharmaceutical Joint Stock Company hereby discloses of the 2025 Semi-Annual Financial Statements to the Hanoi Stock Exchange as follows:

1. Tên tổ chức/ *Name of organization*:

- Mã chứng khoán/ *Stock code*: DTP
- Địa chỉ/ *Address*: Cụm Công nghiệp Hà Bình Phương, xã Thường Tín, thành phố Hà Nội/ *Ha Binh Phuong Industrial Cluster, Thuong Tin Commune, Hanoi city*
- Điện thoại liên hệ/ *Phone*: 0243.3765503 Website: <https://cpc1hn.com.vn/>

2. Nội dung thông tin công bố/ *Disclosed Information*:

Báo cáo tài chính bán niên năm 2025/ *2025 Semi-Annual Financial Statements*

BCTC riêng (TCNY không có công ty con và đơn vị kế toán cấp trên có đơn vị trực thuộc)/ *Separate Financial Statements (For listed organizations without subsidiaries and with subordinate accounting units under the same accounting entity)*;

BCTC hợp nhất (TCNY có công ty con)/ *Consolidated Financial Statements (For listed organizations with subsidiaries)*;



BCTC tổng hợp (TCNY có đơn vị kế toán trực thuộc tổ chức bộ máy kế toán riêng)/ *Combined Financial Statements (For listed organizations with subordinate accounting units that maintain independent accounting records).*

- Các trường hợp thuộc diện phải giải trình nguyên nhân/ *Cases subject to explanation of causes:*

+ Tổ chức kiểm toán đưa ra ý kiến không phải là ý kiến chấp nhận toàn phần đối với BCTC (đối với BCTC đã được soát xét/kiểm toán 2024)/ *The audit firm issues an opinion other than an unqualified opinion on the financial statements (for the reviewed/audited financial statements of the year 2024):*

Có/Yes

Không/No

Văn bản giải trình trong trường hợp tích có/ *Written explanation required if selected "Yes":*

Có/Yes

Không/No

+ Lợi nhuận sau thuế trong kỳ báo cáo có sự chênh lệch trước và sau kiểm toán từ 5% trở lên, chuyển từ lỗ sang lãi hoặc ngược lại (đối với BCTC được kiểm toán năm 2024)/ *Profit after tax in the reporting period differs by 5% or more before and after audit/review, or changes from loss to profit or vice versa (for audited financial statements of the year 2024):*

Có/Yes

Không/No

Văn bản giải trình trong trường hợp tích có/ *Written explanation required if selected "Yes":*

Có/Yes

Không/No

+ Lợi nhuận sau thuế thu nhập doanh nghiệp tại báo cáo kết quả kinh doanh của kỳ báo cáo thay đổi từ 10% trở lên so với báo cáo cùng kỳ năm trước/ *Corporate income tax profit at the financial result of the report changes by 10% or more compared to the same period of the previous year:*

Có/Yes

Không/No

Văn bản giải trình trong trường hợp tích có/ *Written explanation required if selected "Yes":*

Có/Yes

Không/No

+ Lợi nhuận sau thuế trong kỳ báo cáo bị lỗ, chuyển từ lãi ở báo cáo cùng kỳ năm trước sang lỗ ở kỳ này hoặc ngược lại/ *The profit after tax in the reporting period is a loss, switching from profit in the same period of the previous year to a loss in this period or vice versa:*

Có/Yes

Không/No

Văn bản giải trình trong trường hợp tích có/ *Written explanation required if selected "Yes":*

Có/Yes

Không/No

Thông tin này đã được công bố trên trang thông tin điện tử của công ty vào ngày: 14/08/2025 tại đường dẫn: <https://cpc1hn.com.vn/co-dong/bao-cao-tai-chinh>.

This information has been disclosed on the Company's website on August 14, 2025 at the following link: <https://cpc1hn.com.vn/co-dong/bao-cao-tai-chinh>.

Trân trọng/ Sincerely,

Tài liệu đính kèm/ Attachment:

- BCTC bán niên 2025 đã kiểm toán/
Audited semi-annual financial report 2025;
- Văn bản giải trình/ *Explanatory Statement for a 5% Difference.*

ĐẠI DIỆN TỔ CHỨC
Người Ủy quyền công bố thông tin
HA NOI CPC1 PHARMACEUTICAL
JOINT STOCK COMPANY
Authorized Information Disclose Representative



Tạ Thị Hải Huyền



INTERIM FINANCIAL STATEMENTS

HA NOI CPCI PHARMACEUTICAL JOINT STOCK COMPANY

For the period from 01/01/2025 to 30/06/2025

(Reviewed)



CONTENTS

	Page
Report of the Board of Management	02 - 03
Report on review of Interim Financial Statements	04
Reviewed Interim Financial Statements	05 - 42
- Interim Statement of Financial position	05 - 06
- Interim Statement of Income	07
- Interim Statement of Cash flows	08 - 09
- Notes to the Interim Financial Statements	10 - 42



REPORT OF THE BOARD OF MANAGEMENT

The Board of Management of Ha Noi CPC1 Pharmaceutical Joint Stock Company (“the Company”) presents its report and the Company’s Interim Financial Statements for the period from 01/01/2025 to 30/06/2025.

THE COMPANY

Hanoi CPC1 Pharmaceutical Joint Stock Company is established and operates activities under Business Registration Certificate No. 0104089394 dated issued by Hanoi Authority for Planning and Investment for the first time on 05 August 2009, 16th re-registered on 23 March 2023.

The Company’s head office is located at: Ha Binh Phuong Industrial Cluster, Thuong Tin Commune, Hanoi.

BOARD OF DIRECTORS, BOARD OF MANAGEMENT AND BOARD OF SUPERVISION

Members of the Board of Directors during the period and to the reporting date are:

Mr. Le Nam Thang	Chairman
Mr. Nguyen Doan Liem	Member
Mr. Nguyen Thanh Binh	Member
Mr. Tran Nghia Loi	Member

Members of the Board of Management in the period and to the reporting date are:

Mr. Nguyen Thanh Binh	General Director
Mr. Tran Minh Thanh	Vice General Director

Members of the Board of Supervision are:

Ms. Tran Thuy Khanh	Head of Board
Ms. Ha Thi Mai	Member
Ms. Nguyen Thi Kim Oanh	Member

LEGAL REPRESENTATIVE

The legal representative of the Company during the year and until the preparation of this Interim Financial Statement is Mr. Le Nam Thang – Chairman of the Board of Directors.

AUDITORS

The auditors of AASC Auditing Firm Company Limited have taken the review of Interim Financial Statements for the Company.

STATEMENT OF THE BOARD OF MANAGEMENT'S RESPONSIBILITY IN RESPECT OF THE INTERIM FINANCIAL STATEMENTS

The Board of Management is responsible for the Interim Financial Statements which give a true and fair view of the financial position of the Company, its operating results and its cash flows for the period. In preparing those Interim Financial Statements, the Board of Management is required to:

- Establish and maintain of an internal control system which is determined necessary by the Board of Directors and Board of Management to ensure the preparation and presentation of Financial Statements do not contain any material misstatement caused by errors or frauds;
- Select suitable accounting policies and then apply them consistently;
- Make judgments and estimates that are reasonable and prudent;
- State whether applicable accounting standards have been followed, subject to any material departures disclosed and explained in the Interim Financial Statements;
- Prepare the Interim Financial Statements on the basis of compliance with Vietnamese Accounting Standards, Vietnamese Corporate Accounting System and the statutory requirements relevant to preparation and presentation of Interim Financial Statements;
- Prepare the Interim Financial Statements on going concern basis unless it is inappropriate to presume that the Company will continue in business.

The Board of Management is responsible for ensuring that accounting records are kept to reflect the financial position of the Company, with reasonable accuracy at any time and to ensure that the Interim Financial Statements comply with the current State's regulations. It is responsible for safeguarding the assets of the Company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

The Board of Management, confirms that the Interim Financial Statements give a true and fair view of the financial position at 30 June 2025, its operation results and cash flows for the period from 01/01/2025 to 30/06/2025 of Company in accordance with the Vietnamese Accounting Standards, Vietnamese Corporate Accounting System and the statutory requirements relevant to preparation and presentation of Financial Statements.

Other commitments

The Board of Management pledges that the Company complies with Decree No. 155/2020/ND-CP dated 31 December 2020 by Government on detailing and guiding the implementation of a number of articles of the Law on Securities and the Company does not violate the obligations of information disclosure in accordance with the regulations of the Circular No. 96/2020/TT-BTC dated 16 November 2020 issued by the Ministry of Finance guiding the disclosure of information on Securities Market and the Circular No. 68/2024/TT-BTC dated 18 September 2024 issued by Ministry of Finance amending and supplementing some articles of the Circular No. 96/2020/TT-BTC.

On behalf of the Board of Management,



Le Nam Thang

Chairman

Hanoi, 12 August 2025



No: 120825.027/BCTC.KT3

REPORT ON REVIEW OF INTERIM FINANCIAL STATEMENTS

**To: Shareholders, the Board of Directors and Board of Management
Ha Noi CPC1 Pharmaceutical Joint Stock Company**

We have reviewed the Interim Financial Statements of Ha Noi CPC1 Pharmaceutical Joint Stock Company prepared on 12 August 2025, as set out on pages 06 to 42, including: Interim Statement of Financial position as at 30 June 2025, Interim Statement of Income, Interim Statement of Cash flows and Notes to the Interim Financial Statements for the period from 01/01/2025 to 30/06/2025.

Board of Management's responsibility

The Board of Management is responsible for the preparation and presentation of Interim Financial Statements that give a true and fair view in accordance with Vietnamese Accounting Standards, Vietnamese Corporate Accounting System and the statutory requirements relevant to preparation and presentation of Interim Financial Statements and for such internal control as management determines is necessary to enable the preparation of Interim Financial Statements that are free from material misstatement, whether due to fraud or error.

Auditor's responsibility

Our responsibility is to express a conclusion on these Interim Financial Statements based on our review. We conducted our review in accordance with Vietnamese Standards on Review Engagements (VSRE) 2410 - Review of Interim Financial Information Performed by the Independent Auditor of the Entity.

A review of Interim Financial Statements consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Vietnamese Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

Auditor's conclusion

Based on our review, nothing has come to our attention that causes us to believe that the accompanying Interim Financial Statements do not present fairly, in all material respects, of the financial position of Ha Noi CPC1 Pharmaceutical Joint Stock Company as at 30 June 2025, and of the results of its operations and its cash flows for the period from 01/01/2025 to 30/06/2025 in accordance with the Vietnamese Accounting Standards, Vietnamese Corporate Accounting System and the statutory requirements relevant to preparation and presentation of Interim Financial Statements.

AASC Auditing Firm Company Limited



Vu Xuan Bien
Deputy General Director
Registered Auditor No. 0743-2023-002-1
Hanoi, 12 August 2025

T: (84) 24 3824 1990 | F: (84) 24 3825 3973 | 1 Le Phung Hieu, Hanoi, Vietnam



INTERIM STATEMENT OF FINANCIAL POSITION

As at 30 June 2025

Code	ASSETS	Note	30/06/2025 VND	01/01/2025 VND
100	A. CURRENT ASSETS		874,262,747,757	831,625,331,586
110	I. Cash and cash equivalents	3	60,878,102,724	39,923,026,642
111	1. Cash		44,878,102,724	5,923,026,642
112	2. Cash equivalents		16,000,000,000	34,000,000,000
120	II. Short-term investments		-	5,000,000,000
123	1. Held-to-maturity investments		-	5,000,000,000
130	III. Short-term receivables		371,551,166,665	323,331,711,265
131	1. Short-term trade receivables	4	319,610,316,319	294,178,973,988
132	2. Short-term prepayments to suppliers	5	48,405,913,850	26,056,029,675
136	3. Other short-term receivables	6	3,665,988,865	3,227,759,971
137	4. Provision for short-term doubtful debts		(131,052,369)	(131,052,369)
140	IV. Inventories	8	437,105,214,860	457,806,030,430
141	1. Inventories		437,727,600,122	458,576,003,182
149	2. Provision for devaluation of inventories		(622,385,262)	(769,972,752)
150	V. Other short-term assets		4,728,263,508	5,564,563,249
151	1. Short-term prepaid expenses	12	4,001,199,797	4,283,103,450
152	2. Deductible VAT		711,889,516	1,279,022,332
153	3. Taxes and other receivables from the State budget	16	15,174,195	2,437,467
200	B. NON-CURRENT ASSETS		475,377,348,664	450,804,079,781
210	I. Long-term receivables		3,542,051,820	3,576,969,012
216	1. Other long-term receivables	6	3,542,051,820	3,576,969,012
220	II. Fixed assets		395,827,347,804	372,804,359,218
221	1. Tangible fixed assets	10	380,936,333,254	358,103,670,008
222	- Historical costs		722,102,695,143	670,397,525,616
223	- Accumulated depreciation		(341,166,361,889)	(312,293,855,608)
227	2. Intangible fixed assets	11	14,891,014,550	14,700,689,210
228	- Historical costs		22,291,634,763	21,759,934,763
229	- Accumulated amortization		(7,400,620,213)	(7,059,245,553)
240	IV. Long-term assets in progress	9	17,240,259,530	17,120,938,691
242	1. Construction in progress		17,240,259,530	17,120,938,691
260	VI. Other long-term assets		58,767,689,510	57,301,812,860
261	1. Long-term prepaid expenses	12	58,767,689,510	57,301,812,860
270	TOTAL ASSETS		1,349,640,096,421	1,282,429,411,367

INTERIM STATEMENT OF FINANCIAL POSITION

As at 30 June 2025

(continued)

Code CAPITAL	Note	30/06/2025 VND	01/01/2025 VND
300 C. LIABILITIES		309,822,397,053	307,884,788,110
310 I. Current liabilities		285,249,636,452	276,833,027,509
311 1. Short-term trade payables	14	40,953,583,686	79,521,046,475
312 2. Short-term prepayments from customers	15	45,574,504,829	32,612,600,526
313 3. Taxes and other payables to State budget	16	17,392,117,695	17,702,181,709
314 4. Payables to employees		46,315,452,434	65,684,780,139
315 5. Short-term accrued expenses	17	107,154,194	1,013,834,994
319 6. Other short-term payments	18	41,214,869,274	11,717,491,887
320 7. Short-term borrowings and finance lease liabilities	13	43,541,967,159	41,694,687,517
322 8. Bonus and welfare fund		50,149,987,181	26,886,404,262
330 II. Non-current liabilities		24,572,760,601	31,051,760,601
337 1. Other long-term payables	18	202,500,000	131,500,000
338 2. Long-term borrowings and finance lease liabilities	13	23,900,000,000	30,450,000,000
343 3. Science and technology development fund		470,260,601	470,260,601
400 D. OWNER'S EQUITY		1,039,817,699,368	974,544,623,257
410 I. Owner's equity	19	1,039,817,699,368	974,544,623,257
411 1. Contributed capital		324,580,840,000	162,290,420,000
411a - Ordinary shares with voting rights		324,580,840,000	162,290,420,000
412 2. Share Premium		9,442,260,000	9,442,260,000
418 3. Development and investment funds		94,353,394,407	94,353,394,407
421 4. Retained earnings		611,441,204,961	708,458,548,850
421a - Retained earnings accumulated to the end of the previous year		472,568,702,421	471,226,389,269
421b - Retained earnings of the current period		138,872,502,540	237,232,159,581
440 TOTAL CAPITAL		1,349,640,096,421	1,282,429,411,367



Nguyen Thi Xuan Hoan
Preparer
Hanoi, 12 August 2025



Dang Thi Thu Thuy
Chief Accountant



Le Nam Thang
Chairman

INTERIM STATEMENT OF INCOME

From 01/01/2025 to 30/06/2025

Code ITEMS	Note	From 01/01/2025	From 01/01/2024
		to 30/06/2025	to 30/06/2024
		VND	VND
01 1. Revenue from sales of goods and rendering of services	21	725,851,016,538	585,856,595,383
02 2. Revenue deductions	22	2,432,353,330	1,143,967,428
10 3. Net revenue from sales of goods and rendering of services		723,418,663,208	584,712,627,955
11 4. Cost of goods sold and services rendered	23	339,811,110,237	265,342,297,456
20 5. Gross profit from sales of goods and rendering of services		383,607,552,971	319,370,330,499
21 6. Financial income	24	604,305,640	1,046,238,169
22 7. Financial expenses	25	2,957,280,419	4,819,525,765
23 <i>In which: Interest expenses</i>		2,132,292,098	3,161,696,471
25 8. Selling expenses	26	200,557,660,680	166,042,345,884
26 9. General and administrative expenses	27	18,998,601,650	18,780,391,475
30 10. Net profit from operating activities		161,698,315,862	130,774,305,544
31 11. Other income	28	242,006,213	25,480,903
32 12. Other expenses	29	21,354,485,929	494,253,480
40 13. Other profit		(21,112,479,716)	(468,772,577)
50 14. Total net profit before tax		140,585,836,146	130,305,532,967
51 15. Current corporate income tax expenses	30	17,521,164,267	7,516,554,163
52 16. Deferred corporate income tax expenses		-	-
60 17. Profit after corporate income tax		<u>123,064,671,879</u>	<u>122,788,978,804</u>
70 18. Basic earnings per share	31	3,602	3,594


Nguyen Thi Xuan Hoan
Preparer
Hanoi, 12 August 2025


Dang Thi Thu Thuy
Chief Accountant


Le Nam Thang
Chairman



INTERIM STATEMENT OF CASH FLOWS

From 01/01/2025 to 30/06/2025

(Indirect method)

Code	ITEMS	Note	From 01/01/2025 to 30/06/2025 VND	From 01/01/2024 to 30/06/2024 VND
	I. CASH FLOWS FROM OPERATING ACTIVITIES			
01	1. Profit before tax		140,585,836,146	130,305,532,967
	2. Adjustments for			
02	- Depreciation and amortization of fixed assets and investment properties		36,057,041,142	32,858,470,639
03	- Provisions		(147,587,490)	(10,872,362,837)
04	- Exchange gains/losses from retranslation of monetary items denominated in foreign currency		521,352,295	873,211,985
05	- Gains/losses from investment activities		(384,851,266)	(723,532,571)
06	- Interest expenses		2,132,292,098	3,161,696,471
07	- Other adjustments		15,832,201,461	(800,825,840)
08	3. Operating profit before changes in working capital		194,596,284,386	154,802,190,814
09	- Increase/decrease in receivable		(47,627,596,072)	(24,747,009,830)
10	- Increase/decrease in inventories		20,848,403,060	(40,208,467,218)
11	- Increase/decrease in payable (excluding interest payable/ corporate income tax payable)		(49,598,642,823)	(25,251,690,059)
12	- Increase/decrease in prepaid expenses		(1,183,972,997)	739,845,932
14	- Interest paid		(2,192,055,848)	(3,267,366,358)
15	- Corporate income tax paid		(34,719,912,164)	(4,546,300,307)
17	- Other payments on operating activities		(2,069,928,849)	(7,717,635,787)
20	Net cash flows from operating activities		78,052,578,693	49,803,567,187
	II. CASH FLOWS FROM INVESTING ACTIVITIES			
21	1. Purchase or construction of fixed assets and other long-term assets		(57,463,210,829)	(56,289,577,277)
22	2. Proceeds from disposals of fixed assets and other long-term assets		35,000,000	-
23	3. Loans and purchase of debt instruments from other entities		-	(10,000,000,000)
24	4. Collection of loans and resale of debt instrument of other entities		5,000,000,000	-
27	5. Interest and dividend received		349,851,266	723,532,571
30	Net cash flows from investing activities		(52,078,359,563)	(65,566,044,706)

INTERIM STATEMENT OF CASH FLOWS

From 01/01/2025 to 30/06/2025

(Indirect method)

(continued)

Code ITEMS	Note	From 01/01/2025	From 01/01/2024
		to 30/06/2025	to 30/06/2024
		VND	VND
III CASH FLOWS FROM FINANCING ACTIVITIES			
33 1.		38,476,672,774	57,126,042,081
34 2.		(43,502,925,012)	(58,209,089,281)
36 3.		-	(6,679,056,000)
40		(5,026,252,238)	(7,762,103,200)
50		20,947,966,892	(23,524,580,719)
60		39,923,026,642	79,832,556,707
61		7,109,190	2,303,030
70	3	<u>60,878,102,724</u>	<u>56,310,279,018</u>



Nguyen Thi Xuan Hoan
Preparer
Hanoi, 12 August 2025



Dang Thi Thu Thuy
Chief Accountant



Le Nam Thang
Chairman

NOTES TO THE INTERIM FINANCIAL STATEMENTS

From 01/01/2025 to 30/06/2025

1. GENERAL INFORMATION

Form of ownership

Hanoi CPC1 Pharmaceutical Joint Stock Company is established and operates activities under Business Registration Certificate No. 0104089394 dated issued by Hanoi Authority for Planning and Investment for the first time on 05 August 2009, 16th re-registered on 23 March 2023.

The Company's head office is located at: Ha Binh Phuong Industrial Cluster, Thuong Tin Commune, Hanoi.

As of 30/06/2025, the charter capital of the Company is VND 324,580,840,000, equivalent to 32,458,084 shares, the par value of each share is VND 10,000.

The Company is conducting legal procedures to register changes to the content of the Enterprise Registration Certificate in order to update the new charter capital at the business registration office.

The number of employees of the Company as at 30 June 2025 was 1,804 (as at 01 January 2025: 1,871).

Business field

Production and trading of drugs, pharmaceutical chemicals and medicinal materials.

Corporate structure

The Company's member entities are as follows:	Address	Main business activities
Ha Noi CPC1 Pharmaceutical Joint Stock Company - Hanoi Branch	No. 356A Giai Phong Street, Phuong Liet Ward, Hanoi City	Trading in medicine, pharmaceutical chemicals and medicinal materials
Ha Noi CPC1 Pharmaceutical Joint Stock Company - Da Nang Branch, Warehouse in Da Nang	Street No. 2, Hoa Khanh Industrial Park, Lien Chieu Ward, Da Nang City	Trading in medicine, pharmaceutical chemicals and medicinal materials
Ha Noi CPC1 Pharmaceutical Joint Stock Company - Ho Chi Minh Branch	No. 26-28 Han Mo Tu Street, Phu Tho Hoa Ward, Ho Chi Minh City	Trading in medicine, pharmaceutical chemicals and medicinal materials
Representative Office of Joint Stock Company - CPC1 Pharmaceutical Hanoi	No. 181 Thong Nhat Street, Phu Tho Hoa Ward, Ho Chi Minh City	Trading in medicine, pharmaceutical chemicals and medicinal materials
Business location - Ha Noi CPC1 Pharmaceutical Joint Stock Company in Thanh Hoa	MB2125 Lot N27 + N28 Le Hien Tong Street, Hac Thanh Ward, Thanh Hoa Province	Trading in medicine, pharmaceutical chemicals and medicinal materials
Business location - Ha Noi CPC1 Pharmaceutical Joint Stock Company in Hai Phong	HA apartment. S01 Vinhomes Marina Urban Area, An Bien Ward, Hai Phong City	Trading in medicine, pharmaceutical chemicals and medicinal materials
Business location - Ha Noi CPC1 Pharmaceutical Joint Stock Company in Nghe An	Apartment No. 109, 12-storey apartment building in New Urban Area, West Avenue VI.Lenin, Hamlet 19, Vinh Phu Ward, Nghe An Province	Trading in medicine, pharmaceutical chemicals and medicinal materials

The Company's member entities are as follows:	Address	Main business activities
Business location - Ha Noi CPC1 Pharmaceutical Joint Stock Company in Khanh Hoa	Land Lot No. 4, Street No. 93, Thai Hung Urban Area (Package 05 My Gia Urban Area), Nam Nha Trang Ward, Khanh Hoa Province	Trading in medicine, pharmaceutical chemicals and medicinal materials
Business location - Ha Noi CPC1 Pharmaceutical Joint Stock Company in Can Tho	Land plot No. 2158, Map sheet No. 1, street No. 3, Residential Lot No. 11B, Nam Can Tho Urban Area, Hung Phu Ward, Can Tho City	Trading in medicine, pharmaceutical chemicals and medicinal materials
Business location - Ha Noi CPC1 Pharmaceutical Joint Stock Company in Dak Lak	Land Lot No. 2263, 2264, Map sheet No. 19, Buon Ma Thuot Ward, Dak Lak Province	Trading in medicine, pharmaceutical chemicals and medicinal materials
Business location - Ha Noi CPC1 Pharmaceutical Joint Stock Company in Hanoi	1st, 2nd, 3rd Floor, Vinh Quang Group Building, Lot DX, Southwest Urban Area of Linh Dam Lake, Hoang Liet Ward, Hanoi City	Trading in medicine, pharmaceutical chemicals and medicinal materials

2. ACCOUNTING SYSTEM AND ACCOUNTING POLICY

2.1. Accounting period and accounting currency

Annual accounting period commences from 1 January and ends as at 31 December.
 The Company maintains its accounting records in Vietnam Dong (VND).

2.2. Standards and Applicable Accounting Policies

Applicable Accounting Policies

The Company applies Corporate Accounting System issued under the Circular No. 200/2014/TT-BTC dated 22 December 2014 by the Ministry of Finance and the Circular No. 53/2016/TT-BTC dated 21 March 2016 issued by Ministry of Finance amending and supplementing some articles of the Circular No. 200/2014/TT-BTC.

Declaration of compliance with Accounting Standards and Accounting System

The Company applies Vietnamese Accounting Standards and supplementary documents issued by the State. Financial Statements are prepared and presented in accordance with regulations of each standard and supplementary document as well as with current Accounting Standards and Accounting System.

2.3. Basis for preparation of Interim Financial Statements

Interim Financial Statements are presented based on historical cost principle.

Interim Financial Statements of the Company are prepared based on summarization of transactions incurred, then recorded into accounting books of dependent accounting entities and at the offices of the Company.

2.4. Accounting estimates

The preparation of Interim Financial Statements in conformity with Vietnamese Accounting Standards, Vietnamese Corporate Accounting System and legal regulations relating to financial reporting requires the Board of Management to make estimates and assumptions that affect the reported amounts of liabilities, assets and disclosures of contingent liabilities and assets at the date of the separate financial statements and the reported amounts of revenues and expenses during the period.

The estimates and assumptions that have a material impact in the Interim Financial Statements include:

- Provision for doubtful debts
- Provision for devaluation of inventory
- Provision for payables
- Estimated allocation of prepaid expenses
- Estimated useful life of fixed assets
- Classification and provision of financial investments
- Estimated income tax

Such estimates and assumptions are continually evaluated. They are based on historical experience and other factors, including expectations of future events that may have a financial impact on the Company and that are assessed by the Board of Management to be reasonable under the circumstances.

2.5. Financial instruments

Initial recognition

Financial assets

Financial assets of the Company include cash, cash equivalents, trade receivables, other receivables, lending loans. At initial recognition, financial assets are identified by purchasing price/issuing cost plus other expenses directly related to the purchase and issuance of those assets.

Financial liabilities

Financial liabilities of the Company include borrowings, trade payables, other payables and accrued expenses. At initial recognition, financial liabilities are determined by issuing price plus other expenses directly related to the issuance of those liabilities.

Subsequent measurement after initial recognition

Financial assets and financial liabilities are not revalued according to fair value at the end of the year because the Circular No. 210/2009/TT-BTC and prevailing statutory regulations require to present Financial statements and Notes to financial instruments but not provide any relevant instruction for assessment and recognition of fair value of financial assets and financial liabilities.

2.6. Foreign currency transactions

Foreign currency transactions during the period are translated into Vietnam Dong using the actual rate at transaction date.

Actual exchange rate when revaluing monetary items denominated in foreign currencies at the reporting date of Interim Financial Statements is determined under the following principles:

- For asset accounts, applying the bid rate of the commercial bank where the Company regularly conducts transaction;
- For cash deposited in bank, applying the bid rate of the commercial bank where the Company opens its foreign currency accounts;
- For liability accounts, applying the offer rate of the commercial bank where the Company regularly conducts transactions.

All exchange differences arising as a result of transactions or revaluation at the balance sheet date shall be recorded into the financial income or expense in the period.

2.7. Cash and cash equivalents

Cash comprises cash on hand, demand deposits.

Cash equivalents are short-term investments with the maturity of not over than 3 months from the date of investment, that are highly liquid and readily convertible into known amount of cash and that are subject to an insignificant risk of conversion into cash.

2.8. Receivables

The receivables shall be recorded in details in terms of due date, entities receivable, types of currency and other factors according to requirements for management of the Company. The receivables shall be classified into short-term receivables or long-term receivables on the interim financial statements according to their remaining terms at the reporting date.

The provision for doubtful debts is made for receivables that are overdue under an economic contract, a loan agreement, a contractual commitment or a promissory note and for receivables that are not due but difficult to be recovered. Accordingly, the provisions for overdue debts shall be based on the due date stipulated in the initial sale contract, exclusive of the debt rescheduling between contracting parties and the case where the debts are not due but the debtor is in bankruptcy, in dissolution, or missing and making fleeing or estimating the possible losses.

2.9. Inventories

Inventories are initially recognized at original cost including purchase price, processing cost and other costs incurred in bringing the inventories to their location and condition at the time of initial recognition. After initial recognition, at the reporting date, inventories are stated at the lower of cost and net realizable value.

Net realizable value is estimated based on the selling price of the inventory minus the estimated costs for completing the products and the estimated costs needed for their consumption.

The cost of inventory is calculated using weighted average method.

Inventory is recorded by perpetual method.

Provision for devaluation of inventories made at the end of the period is based on the excess of original cost of inventory over their net realizable value.

2.10. Fixed assets, Finance lease fixed assets

Fixed assets (tangible and intangible) are initially stated at the historical cost. During the using time, fixed assets (tangible and intangible) are recorded at cost, accumulated depreciation and carrying amount.

Subsequent measurement after initial recognition

If these costs aument future economic benefits obtained from the use of tangible fixed assets are extended to their initial standards conditions, these costs are capitalized as an incremental in their historical cost.

Other costs incurred after tangible fixed assets have been put into operation such as repair, maintenance and overhaul costs are recognized in the Interim Statement of Income in the period in which the costs are incurred.

Fixed assets are depreciated (amortised) using the straight-line method over their estimated useful lives as follows:

- Buildings, structures	05 - 45 years
- Machinery, equipment	03 - 15 years
- Vehicles, Transportation equipment	06 - 10 years
- Office equipment and furniture	03 - 05 years
- Other fixed assets	02 - 12 years
- Land use rights	45 years
- Management software	03 years

2.11. Construction in progress

Construction in progress includes fixed assets which is being purchased and constructed as at the balance sheet date and is recognised in historical cost. This includes costs of construction, installation of equipment and other direct costs.

2.12. Operating lease

Operating lease is fixed asset leasing in which a significant portion of the risks and rewards of ownership are retained by the lessor. Payments made under operating leases are charged to income statement on a straight-line basis over the period of the lease.

2.13. Prepaid expenses

The expenses incurred but related to operating results of several accounting periods are recorded as prepaid expenses and are allocated to the operating results in the following accounting periods.

The calculation and allocation of long-term prepaid expenses to operating expenses in each accounting period should be based on the nature of those expenses to select a reasonable allocation method and criteria.

Types of prepaid expenses include:

- Prepaid land expenses include prepaid land rental, including those related to leased land for which the Company has received certificate of land use right but not eligible for recording as intangible fixed asset in accordance with the Circular No. 45/2013/TT-BTC dated 25 April 2013 issued by the Ministry of Finance guiding regulation on management, use and depreciation of fixed assets and other expenses related to ensure for the use of leased land. These expenses are recognized in the statement of income on a straight-line basis according to the lease term of the contract.
- Tools and supplies include assets which are possessed by the Company in an ordinary course of business, with historical cost of each asset less than VND 30 million and therefore not eligible for recording as fixed asset under current legal regulations. The historical cost of tools and supplies are allocated on the straight-line basis from 3 months to 36 months.
- Repair and maintenance costs shall be recorded at the historical cost and allocated according to the straight-line method to the cost of not exceeding 03 years.
- Office rental costs and insurance costs are allocated according to the straight-line method from 02 months to 12 months.
- Other prepaid expenses shall be recorded at historical cost and allocated according to the straight-line method for a useful period of not more than 03 years.

2.14. Payables

The payables shall be recorded in details in terms of due date, entities payable, types of currency and other factors according to the requirements for management of the Company. The payables shall be classified into short-term payables or long-term payables on the interim financial statements according to their remaining terms at the reporting date.

2.15. Borrowings

Borrowings shall be recorded in details in terms of lending entities, loan agreement and terms of borrowings. In case of borrowings denominated in foreign currency, they shall be recorded in details in terms of types of currency.

2.16. Borrowing costs

Borrowing costs are recognized as operating expenses in the period, in which it is incurred excepting those which are directly attributable to the construction or production of a qualifying asset are capitalized as part of the cost of that asset in accordance with VAS No. 16 "Borrowing costs". Besides, regarding borrowings serving the construction of fixed assets and investment properties, the interests shall be capitalized even when the construction duration is under 12 months.

2.17. Accrued expenses

Accrued expenses include payables to goods or services received from the suppliers or provided for the customers during the reporting period, but the payments for such goods or services have not been made and other payables such as interest expenses, personal income tax expense, etc. which are recorded as operating expenses of the reporting period.

The recording of accrued expenses as operating expenses during the period shall be carried out under the matching principle between revenues and expenses during the period. Accrued expenses are settled with actual expenses incurred. The difference between accrued and actual expenses is reverted.

2.18. Owner's equity

Owner's equity is stated at actually contributed capital of owners.

Share premium is recorded at the difference between the par value with costs directly attributable to the issuance of shares and issue price of shares (including the case of re-issuing treasury shares) and can be a positive premium (if the issue price is higher than par value and costs directly attributable to the issuance of shares) or negative premium (if the issue price is lower than par value and costs directly attributable to the issuance of shares).

Retained earnings are used to present the Company's operating results (profit, loss) after corporate income tax and profit appropriation or loss handling of the Company.

Dividends payable to shareholders are recorded as payable on the Company's Interim Statement of Financial position after the Resolution of the General Meeting of Shareholders on dividend distribution.

2.19. Revenues

Revenue is recognized when it is probable that the economic benefits, which can be measured reliably, will flow to the Company. Revenue is determined at the fair value of amounts received or expect to get after deducting trade discounts, sales discounts, and sales returns. The following specific recognition criteria must also be satisfied when revenue is recognized:

Revenue from sale of goods:

- The majority of risks and benefits associated with the right to own the products or goods have been transferred to the buyer;
- The company no longer holds the right to manage the goods as the goods owner, or the right to control the goods.

Revenue from rendering of services:

- The percentage of completion of the transaction at the Balance sheet date can be measured reliably.

Financial income

Financial incomes include income from assets yielding interest, royalties, dividends and other financial gains by the company shall be recognised when the two conditions are satisfied:

- It is probable that the economic benefits associated with the transaction will flow to the Company;
- The amount of the revenue can be measured reliably.

Dividend income shall be recognised when the Company's right to receive dividend is established.

2.20. Revenue deductions

Revenue deductions from sales of goods and rendering of services arising in the period include: sales discounts and sales returns.

Sales discounts and sales returns incurred in the same period of sale of goods and rendering of services are recorded as a decrease in revenue in the incurring period. In case goods and services are sold in the previous periods, but until the next period they are incurred as deductible items, the Company records the decrease in revenue under the following principles: If it is incurred prior to the issuance of Financial Statements, it is then recorded as a decrease in revenue on the Financial Statements of the reporting period (the previous period); and if it is incurred after the issuance of Financial Statements, it is recorded as a decrease in revenue of incurring period (the next period).

2.21. Cost of goods sold and services rendered

Cost of goods sold and services rendered are cost of finished goods, merchandises, materials sold or services rendered during the period, and recorded on the basis of matching with revenue and on a prudence basis. Cases of loss of materials and goods exceeded the norm, labour cost and fixed manufacturing overheads not allocated to the value of inventory, provision for devaluation of inventory, abnormal expenses and losses of inventories after deducting the responsibility of collective and individuals concerned, etc. is recognized fully and promptly into cost of goods sold in the period even when products and goods have not been determined as sold.

2.22. Financial expenses

Items recorded into financial expenses comprise:

- Borrowing costs;
- Exchange rate loss.

The above items are recorded by the total amount arising in the period without offsetting against financial income.

2.23. Corporate income tax

a) Current corporate income tax expenses

Current corporate income tax expenses are determined based on taxable income during the period and current corporate income tax rate.

b) Tax incentives

The Company is enjoying tax incentives as follows:

The company is a science and technology enterprise certified under Certificate No. 44/DNKHCN issued for the first time on 19 July 2018 by the Hanoi Department of Science and Technology. Accordingly, the Company is entitled to incentives for exemption and reduction of corporate income tax according to the provisions of Article 12, Decree No. 13/2019/ND-CP dated 01 February 2019 of the Government on science and technology enterprises if it meets the conditions on revenue of products formed from scientific and technological results reaching a minimum rate of 30% of the total revenue of the enterprise karma. Therefore, enterprises are exempt from corporate income tax for 04 years and reduce 50% of payable tax for the next 09 years from 2018.

c) Current corporate income tax rate

For the period from 01/01/2025 to 30/06/2025, the Company applies the corporate income tax rate of 20% for the operating activities which has taxable income.

2.24. Earnings per share

Basic earnings per share are calculated by dividing net profit or loss after tax for the year attributable to ordinary shareholders of the Company (after adjusting for the bonus and welfare fund and allowance for Board of Management) by the weighted average number of ordinary shares outstanding during the period.

2.25. Related Parties

The parties are regarded as related parties if that party has the ability to control or significantly influence the other party in making decisions about the financial policies and activities. The Company's related parties include:

- Companies, directly or indirectly through one or more intermediaries, having control over the Company or being under the control of the Company, or being under common control with the Company, including the Company's parent, subsidiaries and associates;
- Individuals, directly or indirectly, holding voting power of the Company that have a significant influence on the Company, key management personnel including directors and employees of the Company, the close family members of these individuals;
- Enterprises that the above-mentioned individuals directly or indirectly hold an important part of the voting power or have significant influence on these enterprises.

In considering the relationship of related parties to serve for the preparation and presentation of Interim Financial Statements, the Company should consider the nature of the relationship rather than the legal form of the relationship.

2.26. Segment information

Because the Company operates mainly in the field of production and trading of drugs, pharmaceutical chemicals and medicinal materials in the territory of Vietnam, the Company does not make Division Reports by business field and geographical area.

3. CASH AND CASH EQUIVALENTS

	30/06/2025	01/01/2025
	VND	VND
- Cash on hand	648,521,662	895,537,197
- Demand deposits	44,229,581,062	5,027,489,445
- Cash equivalents	16,000,000,000	34,000,000,000
	60,878,102,724	39,923,026,642

On 30 June 2025, cash equivalents are term deposits from 01 week to 01 month with a total value of VND 16,000,000,000 deposited at Asia Commercial Joint Stock Bank - Hanoi Branch with interest rates from 0.5%/year to 4.3%/year.

4. SHORT-TERM TRADE RECEIVABLES

	30/06/2025		01/01/2025	
	Value	Provision	Value	Provision
	VND	VND	VND	VND
Related parties	15,846,355,893	-	9,954,555,937	-
- Tan Thinh Pharmaceutical Co., Ltd.	8,421,005,611	-	2,923,683,600	-
- VNP Pharmaceutical Co., Ltd.	7,389,245,570	-	7,016,907,337	-
- CPC1 Central Pharmaceutical Joint Stock Company - Ho Chi Minh City Branch	5,381,712	-	-	-
- CPC1 Central Pharmaceutical Joint Stock Company - Quang Ninh Branch	30,723,000	-	13,965,000	-
Others	303,763,960,426	-	284,224,418,051	-
- Cho Ray Hospital	5,864,728,800	-	6,953,647,600	-
- Binh Minh Pharmaceutical Co., Ltd.	2,289,587,134	-	3,885,418,637	-
- Thuan Phat Production and Development Investment Co., Ltd.	25,733,305,470	-	24,848,092,599	-
- Novopharm Co., Ltd.	5,923,072,367	-	2,190,666,660	-
- Hung Vuong Medical Equipment and Trading Joint Stock Company	1,030,731,282	-	7,791,276,489	-
- Novopharm Joint Stock Company - GMP Pharmaceutical Factory	13,273,456,982	-	4,420,380,019	-
- Others	249,649,078,391	-	234,134,936,047	-
	319,610,316,319	-	294,178,973,988	-

Ha Noi CPC1 Pharmaceutical Joint Stock Company

 Ha Binh Phuong Industrial Cluster, Thuong Tin
 Commune, Hanoi

Interim Financial Statements

For the period from 01/01/2025 to 30/06/2025

5. SHORT-TERM PREPAYMENTS TO SUPPLIERS

	30/06/2025		01/01/2025	
	Value	Provision	Value	Provision
	VND	VND	VND	VND
<i>Others</i>				
- Phu Quy Construction and Infrastructure Joint Stock Company	2,205,288,965	-	851,358,761	-
- Ha Do Construction M&E - Industrial Equipment Joint Stock Company	8,475,953,882	-	-	-
- Nguyen Loc Technology Co., Ltd.	1,056,703,472	-	-	-
- Ihome Construction Architecture Joint Stock Company	6,999,000,000	-	-	-
- HQC Industrial Joint Stock Company	1,144,141,200	-	-	-
- Quy Long Refrigeration Mechanical and Electrical Engineering Co., Ltd.	-	-	5,203,970,160	-
- Huy Anh Construction and Trading Services Joint Stock Company	5,302,313,580	-	1,748,281,844	-
- Others	23,222,512,751	(131,052,369)	18,252,418,910	(131,052,369)
	48,405,913,850	(131,052,369)	26,056,029,675	(131,052,369)

6. OTHER RECEIVABLES

	30/06/2025		01/01/2025	
	Value	Provision	Value	Provision
	VND	VND	VND	VND
a) Short-term				
a.1) Details by content				
- Advances	3,062,975,401	-	2,233,936,114	-
- Mortgages	562,318,841	-	684,566,797	-
- Other receivables	40,694,623	-	309,257,060	-
	3,665,988,865	-	3,227,759,971	-
a.2) Details by object				
Related parties	50,000,000	-	51,526,600	-
- CPC1 Central Pharmaceutical Joint Stock Company	50,000,000	-	50,000,000	-
- Tan Thinh Pharmaceutical Co., Ltd.	-	-	1,526,600	-
Others	3,615,988,865	-	3,176,233,371	-
- Tho Thanh Tam	91,322,508	-	285,908,452	-
- Le Manh Hiep	583,433,075	-	215,614,488	-
- Asia Commercial Joint Stock Bank (ACB)	412,194,863	-	449,102,363	-
- Others	2,529,038,419	-	2,225,608,068	-
	3,665,988,865	-	3,227,759,971	-

Ha Noi CPC1 Pharmaceutical Joint Stock Company

 Ha Binh Phuong Industrial Cluster, Thuong Tin
 Commune, Hanoi

Interim Financial Statements

For the period from 01/01/2025 to 30/06/2025

b) Long-term
b.1) Details by content

- Mortgages	3,542,051,820	-	3,576,969,012	-
	<u>3,542,051,820</u>	<u>-</u>	<u>3,576,969,012</u>	<u>-</u>

b.2) Details by object

Related parties	400,000,000	-	400,000,000	-
- CPC1 Central Pharmaceutical Joint Stock Company	400,000,000	-	400,000,000	-
Others	3,142,051,820	-	3,176,969,012	-
- Asia Commercial Joint Stock Bank (ACB)	1,732,540,149	-	1,732,540,149	-
- Binh Tien Consumer Goods Manufacturing Co., Ltd. (BIT'S)	600,000,000	-	600,000,000	-
- Duc - Viet Production, Trading and Service Joint Stock Company	400,000,000	-	400,000,000	-
- Other deposits and mortgages	409,511,671	-	444,428,863	-
	<u>3,542,051,820</u>	<u>-</u>	<u>3,576,969,012</u>	<u>-</u>

7. DOUBTFUL DEBTS

	30/06/2025		01/01/2025	
	Original cost	Recoverable value	Original cost	Recoverable value
	VND	VND	VND	VND
- Total value of receivables and debts that are overdue or not due but difficult to be recovered				
Prepayments to suppliers	131,052,369	-	131,052,369	-
+ Viet Scooter Joint Stock Company	127,050,000	-	127,050,000	-
+ Hoa Nhon Printing Co., Ltd.	4,002,369	-	4,002,369	-
	<u>131,052,369</u>	<u>-</u>	<u>131,052,369</u>	<u>-</u>

8. INVENTORIES

	30/06/2025		01/01/2025	
	Original cost	Provision	Original cost	Provision
	VND	VND	VND	VND
- Goods in transit	3,843,040,108	-	13,037,207,591	-
- Raw material	139,721,774,203	(268,728,630)	137,708,935,583	(171,425,088)
- Tools, supplies	110,309,566	-	127,690,574	-
- Work in progress	6,950,754,556	-	10,331,775,450	-
- Finished goods	152,555,382,971	(353,656,632)	152,119,377,011	(598,547,664)
- Goods	134,546,338,718	-	145,251,016,973	-
	<u>437,727,600,122</u>	<u>(622,385,262)</u>	<u>458,576,003,182</u>	<u>(769,972,752)</u>

9. LONG-TERM ASSET IN PROGRESS

	30/06/2025	01/01/2025
	VND	VND
- Procurement of fixed assets	2,853,555,926	2,553,964,000
Technology Piping System Project	2,052,630,000	1,872,114,000
Employee check-in system project	-	531,700,000
Buy Isuzu Truck	800,925,926	-
Other Shopping	-	150,150,000
- Construction in progress	13,719,809,561	11,071,944,358
Factory project in Ha Binh Phuong Industrial Cluster (*)	11,090,985,099	10,238,726,758
Tan Phu Trung factory project (**)	1,915,849,194	833,217,600
Smart Warehouse Project	712,975,268	-
- Major repairs of fixed assets	666,894,043	3,495,030,333
Factory renovation project	666,894,043	3,495,030,333
	<u>17,240,259,530</u>	<u>17,120,938,691</u>

(*) This is a project to invest and build a factory to manufacture medicines, functional foods, and medical equipment GMP according to EU standards. The project is built at the headquarters in Ha Binh Phuong Industrial Cluster, Thuong Tin Commune, Hanoi. The purpose of investment is to improve production productivity, expand the scale of facilities, and meet the Company's production and business needs in the next time. Investment capital comes from own capital and capital mobilized from credit institutions. By 30/06/2025, the project has passed the detailed planning stage of 1/500 and has been granted a Construction Permit, now entering the construction implementation stage.

(**) This is an investment project to build a factory for manufacturing drugs and functional foods, combined with use as a warehouse. The project is implemented at Lot A5-11, D2&N2 Street, in Zone A5, Tan Phu Trung Industrial Park, Cu Chi Commune, Ho Chi Minh City, with a total area of 6,586.9 m².

The goal of the project is to improve production productivity, expand the scale of facilities to meet production and business needs in the coming time. The total investment capital is VND 50 billion, including own capital and capital mobilized from credit institutions.

By 30/06/2025, the project has completed the 1/500 planning procedures and is in the stage of preparing documents to apply for a construction permit.

10. TANGIBLE FIXED ASSETS

	VND	VND	VND	VND	VND	VND	VND	Total
	Buildings, structures	Machinery, equipment	Vehicles, transportation equipment	Office equipment and furniture	Others			
Historical cost								
Beginning balance	142,217,699,785	471,765,169,358	30,546,288,758	921,124,091	24,947,243,624			670,397,525,616
- Purchase in the period	2,129,664,840	23,102,154,921	776,615,482	34,500,000	2,002,462,626			28,045,397,869
- Completed construction investment	10,081,918,141	20,444,738,517	-	-	-			30,526,656,658
- Liquidation, disposal	-	(6,771,000,000)	-	-	-			(6,771,000,000)
- Other decrease	-	(45,260,000)	-	(50,625,000)	-			(95,885,000)
Ending balance of the period	154,429,282,766	508,495,802,796	31,322,904,240	904,999,091	26,949,706,250			722,102,695,143
Accumulated depreciation								
Beginning balance	31,595,517,573	246,898,242,760	18,671,225,980	374,320,637	14,754,548,658			312,293,855,608
- Depreciation in the period	3,068,690,083	28,723,066,117	2,026,388,915	153,090,064	1,744,431,303			35,715,666,482
- Liquidation, disposal	-	(6,771,000,000)	-	-	-			(6,771,000,000)
- Other decrease	-	(45,260,000)	-	(26,900,201)	-			(72,160,201)
Ending balance of the period	34,664,207,656	268,805,048,877	20,697,614,895	500,510,500	16,498,979,961			341,166,361,889
Net carrying amount								
Beginning balance	110,622,182,212	224,866,926,598	11,875,062,778	546,803,454	10,192,694,966			358,103,670,008
Ending balance	119,765,075,110	239,690,753,919	10,625,289,345	404,488,591	10,450,726,289			380,936,333,254

In which:

- The carrying amount of tangible fixed assets pledged as collaterals for borrowings at the end of the period: VND 178,804,073,683.
- Cost of fully depreciated tangible fixed assets but still in use at the end of the period: VND 93,917,970,273.

11. INTANGIBLE FIXED ASSETS

	Land use rights (*)	Computer software	Total
	VND	VND	VND
Historical cost			
Beginning balance	20,260,434,763	1,499,500,000	21,759,934,763
- Completed capital construction investment	-	531,700,000	531,700,000
Ending balance of the period	20,260,434,763	2,031,200,000	22,291,634,763
Accumulated amortization			
Beginning balance	5,850,375,179	1,208,870,374	7,059,245,553
- Amortization in the period	225,157,182	116,217,478	341,374,660
Ending balance of the period	6,075,532,361	1,325,087,852	7,400,620,213
Net carrying amount			
Beginning balance	14,410,059,584	290,629,626	14,700,689,210
Ending balance	14,184,902,402	706,112,148	14,891,014,550

(*) The land use right is valid until 29 May 2057 in Ha Binh Phuong Industrial Park, Thuong Tin Commune, Hanoi City with a total area of 30,306.3 m² which is being used as the Company's headquarters and GMP-WHO Pharmaceutical Factory with a historical cost of VND 20,260,434,763.

In which:

- Cost of fully amortized intangible fixed assets but still in use at the end of the period: VND 1,119,500,000.

12. PREPAID EXPENSES

	30/06/2025	01/01/2025
	VND	VND
a) Short-term prepaid expenses		
- Dispatched tools and supplies	1,574,665,048	1,279,731,556
- Office Rental Cost	1,362,600,000	2,072,400,000
- Cost of Insurance	151,249,994	116,912,006
- Others	912,684,755	814,059,888
	4,001,199,797	4,283,103,450
b) Long-term prepaid expenses		
- Prepaid land and infrastructure rent in Tan Phu Trung Industrial Park (*)	11,384,405,811	11,577,908,458
- Land use rights in Hoa Khanh Expanded Industrial Park (**)	13,542,852,358	13,778,380,228
- Dispatched tools and supplies	22,230,538,966	20,413,558,074
- Repair and maintenance costs	9,277,217,988	9,486,939,560
- Others	2,332,674,387	2,045,026,540
	58,767,689,510	57,301,812,860

(*) Land rent and infrastructure is a one-time payment for a land area of 6,586.9 m² in Tan Phu Trung Industrial Park, Cu Chi Commune, Ho Chi Minh City with Saigon Tay Bac Urban Development Joint Stock Company. The land lease period is from the time of signing the official land lease contract on 10 June 2022 to 16 December 2054. The company makes allocation according to the lease period of the contract.

(**) The land use rights with a total area of 7,694.0 m² in Hoa Khanh Expanded Industrial Park, Lien Chieu Ward, Da Nang City are transferred according to the contract signed on 17 October 2024 between Ha Noi CPC1 Pharmaceutical Joint Stock Company and Thanh Hoang Chau One Member Co., Ltd.

The purpose of buying land is to invest in a warehouse for goods. The land use period under the land use right certificate is until 25 March 2054. The company allocates according to the remaining time of the land use right certificate.

Interim Financial Statements
For the period from 01/01/2025 to 30/06/2025

Ha Noi CPC1 Pharmaceutical Joint Stock Company
Ha Binh Phuong Industrial Cluster, Thuong Tin Commune, Hanoi

13. BORROWINGS

	01/01/2025		During the period		30/06/2025	
	Outstanding balance	Amount can be paid	Increase	Decrease	Outstanding balance	Amount can be paid
	VND	VND	VND	VND	VND	VND
a) Short-term borrowings						
- Short-term debts	28,694,687,517	28,694,687,517	38,802,468,654	37,055,189,012	30,441,967,159	30,441,967,159
+ Joint Stock Commercial Bank for Foreign Trade of Vietnam - Nam Thang Long Branch	8,304,141,275	8,304,141,275	12,777,129,099	13,038,751,275	8,042,519,099	8,042,519,099
+ Asia Commercial Joint Stock Bank - Hanoi Branch - Times City Transaction Office	19,882,306,242	19,882,306,242	26,025,339,555	23,508,197,737	22,399,448,060	22,399,448,060
+ Military Commercial Joint Stock Bank	508,240,000	508,240,000	-	508,240,000	-	-
- Current portion of long-term debts	13,000,000,000	13,000,000,000	6,550,000,000	6,450,000,000	13,100,000,000	13,100,000,000
+ Asia Commercial Joint Stock Bank - Hanoi Branch - Times City Transaction Office	5,500,000,000	5,500,000,000	2,750,000,000	2,750,000,000	5,500,000,000	5,500,000,000
+ Joint Stock Commercial Bank for Investment and Development of Vietnam	7,500,000,000	7,500,000,000	3,800,000,000	3,700,000,000	7,600,000,000	7,600,000,000
	41,694,687,517	41,694,687,517	45,352,468,654	43,505,189,012	43,541,967,159	43,541,967,159
b) Long-term borrowings						
- Long-term debts	43,450,000,000	43,450,000,000	-	6,450,000,000	37,000,000,000	37,000,000,000
+ Asia Commercial Joint Stock Bank - Hanoi Branch - Times City Transaction Office	8,250,000,000	8,250,000,000	-	2,750,000,000	5,500,000,000	5,500,000,000
+ Joint Stock Commercial Bank for Investment and Development of Vietnam	35,200,000,000	35,200,000,000	-	3,700,000,000	31,500,000,000	31,500,000,000
	43,450,000,000	43,450,000,000	-	6,450,000,000	37,000,000,000	37,000,000,000
Amount due for settlement within 12 months	(13,000,000,000)	(13,000,000,000)	(6,550,000,000)	(6,450,000,000)	(13,100,000,000)	(13,100,000,000)
Amount due for settlement after 12 months	30,450,000,000	30,450,000,000			23,900,000,000	23,900,000,000

Ha Noi CPC1 Pharmaceutical Joint Stock Company
Ha Binh Phuong Industrial Cluster, Thuong Tin Commune, Hanoi

Interim Financial Statements
For the period from 01/01/2025 to 30/06/2025

Detailed information on Short-term borrowings:

	Currency	Interest Rate	Maturity	Loan purpose	Guarantee	30/06/2025		01/01/2025	
						VND	USD	VND	USD
Others									
Joint Stock Commercial Bank for Foreign Trade of Vietnam - Nam Thang Long Branch (Contract No. NTL-HDCV/24024)	VND	4.4%	6 months from the date of disbursement according to debt acceptance contracts	Replenishment of working capital	Savings deposit balance owned by Mr. Le Nam Thang under the Savings Deposit Balance Pledge Contract No. NTL-HDCC/24031	30,441,967,159		28,694,687,517	
Asia Commercial Joint Stock Bank - Hanoi Branch - Times City Transaction Office (Contract No. BMA.DN.6602.170425)	USD	3.8% - 4.0%	8 months from the date of disbursement according to debt acceptance contracts	Replenishment of working capital	Pharmaceutical factory, machinery and equipment in Ha Binh Phuong Industrial Cluster, Van Binh Commune, Thuong Tin District, Hanoi (currently Thuong Tin Commune, Hanoi).	22,399,448,060		19,882,306,242	
Military Commercial Joint Stock Bank (Contract No. 231723.24.061.2537776.TD)	VND	5.0%	6 months from the date of disbursement according to debt	Replenishment of working capital	Unsecured	-		508,240,000	
						30,441,967,159		28,694,687,517	

Loans from banks and other credit institutions are secured by mortgage/pledge contracts with capital lenders and have been fully registered for secured transactions.

Ha Noi CPC1 Pharmaceutical Joint Stock Company
 Ha Binh Phuong Industrial Cluster, Thuong Tin Commune, Hanoi

Interim Financial Statements
 For the period from 01/01/2025 to 30/06/2025

Detailed information on Long-term borrowings:

	Currency	Interest Rate	Date due	Loan purpose	Guarantee	30/06/2025	01/01/2025
						VND	VND
Others							
Asia Commercial Joint Stock Bank - Hanoi Branch - Times City Transaction Office (Contract No. BMA. DN.328.121217)	VND	8.5%	19/04/2026	Investment in BFS 460-15 technology production line system	BFS 460 machine system and factory, machinery and equipment at the Company	37,000,000,000	43,450,000,000
Joint Stock Commercial Bank for Investment and Development of Vietnam (Contract No. 01/2021/3383375/HDTC)	VND	7.2% (in the first year, then adjust the float periodically 1 year 2 times)	07/09/2029	Investment in machinery and equipment for the production of sterile plastic tubes for medicines	Machinery and equipment system for the production of sterile plastic pipes for medicines: - Model 460-15 manufactured in 2022	31,500,000,000	35,200,000,000
						37,000,000,000	43,450,000,000
						(13,100,000,000)	(13,000,000,000)
						23,900,000,000	30,450,000,000

Amount due for settlement within 12 months

Amount due for settlement after 12 months

Loans from banks and other credit institutions are secured by mortgage/pledge contracts with capital lenders and have been fully registered for secured transactions.

14. SHORT-TERM TRADE PAYABLES

	30/06/2025		01/01/2025	
	Value	Amount can be paid	Value	Amount can be paid
	VND	VND	VND	VND
Related parties	827,489,688	827,489,688	960,941,016	960,941,016
- Tan Thinh Pharmaceutical Co., Ltd.	827,489,688	827,489,688	960,941,016	960,941,016
Others	40,126,093,998	40,126,093,998	78,560,105,459	78,560,105,459
- Phuong Linh Pharmaceutical Trading Co., Ltd.	-	-	9,558,229,368	9,558,229,368
- Thuan Phat Production and Development Investment Co., Ltd.	444,134,613	444,134,613	363,261,366	363,261,366
- Novopharm Co., Ltd.	1,532,474,871	1,532,474,871	2,087,198,447	2,087,198,447
- Hong Ha Printing Joint Stock Company	1,010,859,295	1,010,859,295	920,190,208	920,190,208
- Minh An Pharmaceutical and Cosmetic Joint Stock Company	-	-	5,695,342,774	5,695,342,774
- Duc Thanh Packaging and Trading Manufacturing Co., Ltd.	3,600,195,802	3,600,195,802	2,636,801,834	2,636,801,834
- Song Lam Packaging Trading and Manufacturing Joint Stock Company	1,612,376,935	1,612,376,935	1,846,988,924	1,846,988,924
- Phuc Thai Pharmaceutical Joint Stock Company	1,440,567,500	1,440,567,500	2,288,299,000	2,288,299,000
- Eastern Europe Trading and Manufacturing Co., Ltd.	1,112,074,332	1,112,074,332	3,136,314,203	3,136,314,203
- Others	29,373,410,650	29,373,410,650	50,027,479,335	50,027,479,335
	40,953,583,686	40,953,583,686	79,521,046,475	79,521,046,475

15. SHORT-TERM PREPAYMENTS FROM CUSTOMERS

	30/06/2025	01/01/2025
	VND	VND
Others		
- DP Euphar Joint Stock Company	573,613,533	588,000,000
- Phu An Pharmaceutical and Cosmetic Co., Ltd.	504,000,000	176,400,000
- Hoang Son Pharmaceutical Trading Joint Stock Company	684,541,050	738,000,000
- Bao Minh Pharmaceutical Joint Stock Company	-	251,370,000
- Sanophar Pharmaceutical Co., Ltd.	462,682,500	2,384,146,730
- VITAFARMA S.A.	2,314,283,302	-
- JING WEI KANG KANG TRADING LIMITED	2,498,771,400	442,225,000
- Others	38,536,613,044	28,032,458,796
	45,574,504,829	32,612,600,526

16. TAX AND PAYABLES FROM STATE BUDGET

	Tax receivable at the beginning of period	Tax payable at the beginning of period	Tax payable in the period	Tax paid in the period	Tax receivable at the end of the period	Tax payable at the end of the period
	VND	VND	VND	VND	VND	VND
Value-added tax	2,437,467	787,585,833	8,170,088,910	6,981,466,037	15,174,195	1,988,945,434
Value Added Tax on Imports	-	-	7,962,997,005	7,962,997,005	-	-
Export, import duties	-	-	626,272,818	626,272,818	-	-
Corporate income tax	-	15,448,435,502	33,329,640,929	34,719,912,164	-	14,058,164,267
Personal income tax	-	1,466,160,374	7,896,950,069	8,018,102,449	-	1,345,007,994
Land tax and land rental	-	-	451,398,556	451,398,556	-	-
Other taxes	-	-	213,680,194	213,680,194	-	-
Fees, charges and other payables	-	-	3,800,303,722	3,800,303,722	-	-
	2,437,467	17,702,181,709	62,451,332,203	62,774,132,945	15,174,195	17,392,117,695

The Company's tax settlements are subject to examination by the tax authorities. Because the application of tax laws and regulations on many types of transactions is susceptible to varying interpretations, amounts reported in the Interim Financial Statements could be changed at a later date upon final determination by the tax authorities.

17. SHORT-TERM ACCRUED EXPENSES

	30/06/2025	01/01/2025
	VND	VND
- Interest expense	-	59,763,750
- Expenses for pre-deduction of PIT payable	-	946,371,244
- Other accrued expenses	107,154,194	7,700,000
	107,154,194	1,013,834,994

18. OTHER PAYABLES

	30/06/2025	01/01/2025
	VND	VND
a) Short-term		
a.1) Details by content		
- Trade union fee	493,718,586	2,061,323,586
- Social insurance	1,894,302,500	70,696,500
- Health insurance	337,783,500	-
- Unemployment insurance	148,406,000	-
- Dividend, profit payables	32,458,084,000	-
- Advance payment for entrusted goods	-	6,151,817,546
- Retained amounts of officials and employees	3,424,390,260	3,129,339,675
- Others	2,458,184,428	304,314,580
	41,214,869,274	11,717,491,887
a.2) Details by object		
Related parties	28,802,282,000	5,934,817,546
- VNP Pharmaceutical Co., Ltd.	-	5,871,817,546
- Remuneration of the Board of Directors, Supervisory Board	63,000,000	63,000,000
- Dividends payable to related party shareholders	28,739,282,000	-
Others	12,412,587,274	11,654,491,887
- Officials and employees	3,424,390,260	3,129,339,675
- Dividends payable to shareholders	3,718,802,000	-
- VIETTEL Post Joint Stock Corporation	576,394,014	-
- Other payables	4,693,001,000	8,525,152,212
	41,214,869,274	17,589,309,433
b) Long-term		
b.1) Details by content		
- Long-term deposits, collateral received	202,500,000	131,500,000
	202,500,000	131,500,000

Ha Noi CPC1 Pharmaceutical Joint Stock Company
Ha Binh Phuong Industrial Cluster, Thuong Tin Commune, Hanoi

Interim Financial Statements
For the period from 01/01/2025 to 30/06/2025

19. OWNER'S EQUITY

a) Changes in owner's equity

	Contributed capital	Share premium	Development and investment funds	Retained earnings	Total
	VND	VND	VND	VND	VND
Beginning balance of previous period	162,290,420,000	9,442,260,000	94,353,394,407	524,687,482,670	790,773,557,077
Profit for previous period	-	-	-	122,788,978,804	122,788,978,804
Profit distribution	-	-	-	(53,461,093,401)	(53,461,093,401)
<i>Dividend Distribution</i>	-	-	-	(24,343,563,000)	(24,343,563,000)
<i>Appropriation to the bonus fund for the Board of Directors and the Supervisory Board</i>	-	-	-	(72,000,000)	(72,000,000)
<i>Appropriation to the bonus fund for the Executive Board</i>	-	-	-	(18,200,719,586)	(18,200,719,586)
<i>Appropriation to the bonus and welfare fund</i>	-	-	-	(10,844,810,815)	(10,844,810,815)
Ending balance of previous period	162,290,420,000	9,442,260,000	94,353,394,407	594,015,368,073	860,101,442,480
Beginning balance of current period	162,290,420,000	9,442,260,000	94,353,394,407	708,458,548,850	974,544,623,257
Increase in capital of current period	162,290,420,000	-	-	-	162,290,420,000
Profit for current period	-	-	-	123,064,671,879	123,064,671,879
Profit distribution (*)	-	-	-	(220,082,015,768)	(220,082,015,768)
<i>Stock dividend distribution</i>	-	-	-	(162,290,420,000)	(162,290,420,000)
<i>Cash dividend distribution</i>	-	-	-	(32,458,084,000)	(32,458,084,000)
<i>Appropriation to the bonus and welfare fund</i>	-	-	-	(11,861,607,979)	(11,861,607,979)
<i>Appropriation to the bonus fund for the Board of Directors and the Supervisory Board</i>	-	-	-	(72,000,000)	(72,000,000)
<i>Appropriation to the bonus fund for the Executive Board</i>	-	-	-	(13,399,903,789)	(13,399,903,789)
Ending balance of current period	324,580,840,000	9,442,260,000	94,353,394,407	611,441,204,961	1,039,817,699,368

Ha Noi CPC1 Pharmaceutical Joint Stock Company

Ha Binh Phung Industrial Cluster, Thuong Tin Commune, Hanoi

Interim Financial Statements

For the period from 01/01/2025 to 30/06/2025

(* According to the Resolution of the General Meeting of Shareholders No. 190/2025/NQ-DHDCD dated 29 April 2025, the Company announces the distribution of profits as follows:

(1) Appropriation of funds:

- + Deduction of reward and welfare fund: 5% of after-tax profit in 2024, equivalent to VND 11,861,607,979.
- + Deduction of bonus funds for the Board of Directors and the Supervisory Board: VND 72,000,000.
- + Deduction of the Executive Board bonus fund: VND 13,399,903,789.
- (2) Dividend payment in 2024:
 - + By shares: 100% of the current charter capital, equivalent to the conversion value of VND 162,290,420,000.
 - + In cash: 10% of the expected charter capital after the issuance of stock dividends, equivalent to VND 32,458,084,000.

The company has paid dividends in shares as follows:

- Number of shares issued to pay dividends: 16,229,042 shares;
- Dividend payment rate in 2024 in shares: 100%/ charter capital;
- Right exercise ratio: 1:1 (shareholders who own 01 share are entitled to receive 01 new share);
- Total value of issued shares at par value: VND 162,290,420,000;
- Source of issuance: Undistributed after-tax profit as of 31/12/2024;
- Issuer: Existing shareholders named in the list of Shareholders of the Company on the last date of registration exercise the right to receive dividends in shares as prescribed.

The Company has issued Notice No. 256/2025/BC-DTP dated 17/06/2025 announcing a change in the number of voting shares. Accordingly:

- + Charter capital is adjusted to increase by VND 162,290,420,000, from VND 162,290,420,000 to VND 324,580,840,000;
 - + The number of outstanding shares increased by 16,229,042 shares, from 16,229,042 to 32,458,084 shares.
- The Company has been approved by the Securities Commission for the capital increase in Document No. 2709/UBCK-QLCB dated 23 June 2025.

In addition, according to the above Resolution, the Company has also recorded a dividend payable to shareholders in cash at the rate of 10% of charter capital (after paying dividends in shares), equivalent to the amount of VND 32,458,084,000 (details in Explanation No. 18a). Currently, the Company has not paid this dividend.

b) Details of Contributed capital

	30/06/2025	Rate	01/01/2025	Rate
	VND	%	VND	%
CPC1 Central Pharmaceutical Joint Stock Company	53,333,320,000	16.43	26,666,660,000	16.43
Le Thi Kim Anh	55,799,980,000	17.19	27,899,990,000	17.19
Nguyen Tien Lung	26,666,660,000	8.22	13,333,330,000	8.22
Le Nam Thang	32,015,080,000	9.86	15,007,540,000	9.25
Nguyen Thanh Binh	62,573,300,000	19.28	31,286,650,000	19.28
Phung Thanh Huong	33,279,980,000	10.25	16,639,990,000	10.25
Others	60,912,520,000	18.77	31,456,260,000	19.38
	324,580,840,000	100	162,290,420,000	100

c) Capital transactions with owners and distribution of dividends and profits

	From 01/01/2025 to 30/06/2025	From 01/01/2024 to 30/06/2024
	VND	VND
Owner's contributed capital		
- At the beginning of period	162,290,420,000	162,290,420,000
- Increase in the period	162,290,420,000	-
- At the ending of period	324,580,840,000	162,290,420,000
Distributed dividends and profit		
- Dividend payable at the beginning of the period	-	-
- Dividend payable in the period	194,748,504,000	24,343,563,000
+ Dividend payable from last year's profit	194,748,504,000	24,343,563,000
- Dividend paid in cash in the period	-	(6,679,056,000)
+ Dividend paid from last year's profit	-	(6,679,056,000)
- Dividend paid in shares in the period	(162,290,420,000)	-
+ Dividend paid from last year's profit	(162,290,420,000)	-
- Dividend payable at the end of the period	32,458,084,000	17,664,507,000

d) Share

	30/06/2025	01/01/2025
	VND	VND
Quantity of Authorized issuing shares	32,458,084	16,229,042
Quantity of issued shares and full capital contribution	32,458,084	16,229,042
- Common shares	32,458,084	16,229,042
Quantity of outstanding shares in circulation	32,458,084	16,229,042
- Common shares	32,458,084	16,229,042
Par value per share (VND)	10,000	10,000

e) Company's reserves

	30/06/2025	01/01/2025
	VND	VND
- Development and investment funds	94,353,394,407	94,353,394,407
	94,353,394,407	94,353,394,407

20. OFF STATEMENT OF FINANCIAL POSITION ITEMS AND OPERATING LEASE COMMITMENT

a) Operating leased assets

Name/Location	Purpose of Lease
- Land Plot Lot A5-1, D2 & N2 Street, Zone A5, Tan Phu Trung Industrial Park, Cu Chi Commune, Ho Chi Minh City	Implementation of investment projects
- Land plot in Ha Binh Phuong Industrial Cluster, Thuong Tin commune, Hanoi City	GMP-WHO Pharmaceutical Factory
- No. 356A Giai Phong Street, Phuong Liet Ward, Hanoi City	Hanoi Branch Office
- Street No. 2, Hoa Khanh Industrial Park, Lien Chieu Ward, Da Nang City	Da Nang branch office, warehouse
- No. 26-28 Han Mo Tu Street, Phu Tho Hoa Ward, Ho Chi Minh City	Ho Chi Minh Branch Office
- No. 181 Thong Nhat Street, Phu Tho Hoa Ward, Ho Chi Minh City	Representative Office
- MB2125 Lot N27 + N28 Le Hien Tong Street, Hac Thanh Ward, Thanh Hoa Province	Business Location
- HA Apartment. S01 Vinhomes Marina Urban Area, An Bien Ward, Hai Phong City	Business Location
- Apartment No. 109, 12-storey apartment building in New Urban Area, West Avenue VI.Lenin, Hamlet 19, Vinh Phu Ward, Nghe An Province	Business Location
- Land Lot No. 4, Street No. 93, Thai Hung Urban Area (Package 05 My Gia Urban Area), Nam Nha Trang Ward, Khanh Hoa Province	Business Location
- Land plot No. 2158, map sheet No. 1, street No. 3, Residential Lot No. 11B, Nam Can Tho urban area, Hung Phu ward, Can Tho City	Business Location
- Land Lot No. 2263, 2264, Map No. 19, Buon Ma Thuot Ward, Dak Lak Province	Business Location
- 1st, 2nd, 3rd floor of Vinh Quang Group Building, DX lot, Southwest urban area of Linh Dam Lake, Hoang Liet Ward, Hanoi City	Transaction offices, warehouses

b) Foreign currencies

	30/06/2025	01/01/2025
- USD	160,492.77	30,618.67
- EUR	410.26	-

21. TOTAL REVENUE FROM SALES OF GOODS AND RENDERING OF SERVICES

	From 01/01/2025 to 30/06/2025	From 01/01/2024 to 30/06/2024
	VND	VND
Revenue from sale of goods	725,726,908,588	585,587,616,517
Revenue from rendering of services	124,107,950	268,978,866
	<u>725,851,016,538</u>	<u>585,856,595,383</u>
In which: Revenue from related parties (Detailed in Note No.36)	<u>46,528,500,503</u>	<u>34,864,516,430</u>

22. REVENUE DEDUCTIONS

	From 01/01/2025 to 30/06/2025	From 01/01/2024 to 30/06/2024
	VND	VND
Sale return	1,526,997,150	1,140,928,623
Sale discounts	905,356,180	3,038,805
	2,432,353,330	1,143,967,428
In which: Revenue from related parties (Detailed in Note No. 36)	175,605,650	45,847,584

23. COSTS OF GOODS SOLD AND SERVICES RENDERED

	From 01/01/2025 to 30/06/2025	From 01/01/2024 to 30/06/2024
	VND	VND
Cost of goods sold	339,958,697,727	261,490,747,757
Provision/(backup return) inventory price reduction	(147,587,490)	3,851,549,699
	339,811,110,237	265,342,297,456
In which: Cost of goods sold to related parties (Detailed in Note No.36)	14,382,882,315	8,273,934,315

24. FINANCIAL INCOME

	From 01/01/2025 to 30/06/2025	From 01/01/2024 to 30/06/2024
	VND	VND
Interest income	349,851,266	723,532,571
Gain on exchange difference in the period	254,454,374	322,705,598
	604,305,640	1,046,238,169

25. FINANCIAL EXPENSES

	From 01/01/2025 to 30/06/2025	From 01/01/2024 to 30/06/2024
	VND	VND
Interest expenses	2,132,292,098	3,161,696,471
Loss on exchange difference in the period	303,636,026	784,617,309
Loss on exchange difference at the period - end	521,352,295	873,211,985
	2,957,280,419	4,819,525,765

26. SELLING EXPENSES

	From 01/01/2025 to 30/06/2025	From 01/01/2024 to 30/06/2024
	VND	VND
Tools, instruments and office supplies expenses	3,429,557,247	2,397,999,062
Labour expenses	128,812,371,992	108,276,345,392
Depreciation expenses	2,511,709,887	2,102,107,483
Promotion and sponsorship expenses	2,971,183,172	3,120,607,234
Expenses of outsourcing services	47,186,857,829	43,156,374,134
Other expenses in cash	15,645,980,553	6,988,912,579
	200,557,660,680	166,042,345,884
In which: Selling expenses purchased from related parties (Detailed in Note No.36)	661,117,257	407,266,220

27. GENERAL AND ADMINISTRATIVE EXPENSES

	From 01/01/2025 to 30/06/2025	From 01/01/2024 to 30/06/2024
	VND	VND
Tools, instruments and office supplies expenses	540,223,028	2,382,996,670
Labour expenses	8,712,674,504	5,587,774,287
Depreciation expenses	1,324,129,136	1,260,013,753
Provision expenses	-	276,087,464
Tax, Charge, Fee	1,138,754,734	716,301,206
Expenses of outsourcing services	5,361,641,605	6,655,098,850
Other expenses in cash	1,921,178,643	1,902,119,245
	18,998,601,650	18,780,391,475

28. OTHER INCOME

	From 01/01/2025 to 30/06/2025	From 01/01/2024 to 30/06/2024
	VND	VND
Gain from liquidation, disposal of fixed assets	35,000,000	-
Others	207,006,213	25,480,903
	242,006,213	25,480,903

29. OTHER EXPENSES

	From 01/01/2025 to 30/06/2025	From 01/01/2024 to 30/06/2024
	VND	VND
Loss from revaluation of assets	23,724,799	-
Non-deductible depreciation expense	67,704,060	67,704,060
CIT payable in the previous year	15,807,830,661	-
Fines	5,424,094,203	396,904,882
Others	31,132,206	29,644,538
	21,354,485,929	494,253,480

30. CURRENT CORPORATE INCOME TAX EXPENSES

	From 01/01/2025 to 30/06/2025	From 01/01/2024 to 30/06/2024
	VND	VND
Income subject to CIT:		
Total profit before tax	140,585,836,146	130,305,532,967
Increase	21,394,948,582	535,284,262
- <i>Ineligible expenses</i>	<i>21,394,948,582</i>	<i>535,284,262</i>
CIT taxable income	161,980,784,728	130,840,817,229
Taxable income from preferential activities	148,749,926,786	124,344,061,887
Taxable income from non-preferential activities	13,230,857,942	6,496,755,342
Current CIT expenses	17,521,164,267	7,516,554,163
Current CIT expenses of preferential activities	14,874,992,679	12,434,406,189
Current CIT expenses of non-preferential activities	2,646,171,588	1,299,351,068
CIT is reduced	-	(6,217,203,094)
CIT adjustments of previous years to corporate income tax payable in current period	15,808,476,662	-
Total CIT payable	33,329,640,929	7,516,554,163
Tax payable at the beginning of period	15,448,435,502	2,576,300,307
Tax paid in the period	(34,719,912,164)	(4,546,300,307)
Corporate income tax payable at the end of the period	14,058,164,267	5,546,554,163

31. BASIC EARNINGS PER SHARE

Basic earnings per share distributed to common shareholders of the Company are calculated as follows:

	From 01/01/2025 to 30/06/2025	From 01/01/2024 to 30/06/2024
	VND	VND
Net profit after tax	123,064,671,879	122,788,978,804
Adjustments	(6,153,233,594)	(6,139,448,940)
- <i>Provisional allocation to the bonus and welfare fund (*)</i>	<i>(6,153,233,594)</i>	<i>(6,139,448,940)</i>
Profit distributed to common shares	116,911,438,285	116,649,529,864
Average number of outstanding common shares in circulation in the period	32,458,084	32,458,084
Basic earnings per share	3,602	3,594

(*) The provisional appropriation to the bonus and welfare fund for the first six months of 2025 is estimated based on the appropriation rate approved in Resolution No. 190/2025/NQ-DHDCD dated 29 April 2025 of the Annual General Meeting of Shareholders 2025.

Basic earnings per share have been adjusted retrospectively as regulated by the Vietnamese Accounting Standards No. 30 – Basic earnings per share.

As at 30 June 2025, the Company does not have shares with dilutive potential for earnings per share.

32. BUSINESS AND PRODUCTIONS COST BY ITEMS

	From 01/01/2025 to 30/06/2025	From 01/01/2024 to 30/06/2024
	VND	VND
Tools, instruments and office supplies expenses	13,879,327,888	12,719,091,808
Raw materials	151,432,490,334	137,879,740,298
Labour expenses	178,364,397,310	149,267,046,483
Depreciation expenses	35,989,337,082	32,790,766,579
Provision expenses	-	276,087,464
Taxes, fees and charges	1,138,754,734	716,301,206
Promotion and sponsorship expenses	2,971,183,172	3,120,607,234
Expenses of outsourcing services	61,286,923,780	57,013,777,346
Other expenses in cash	27,455,859,886	12,942,221,382
	<u>472,518,274,186</u>	<u>406,725,639,800</u>

33. FINANCIAL INSTRUMENTS**Financial risk management**

The Company's financial risks include market risk, credit risk and liquidity risk. The Company has developed its control system to ensure the reasonable balance between cost of incurred risks and cost of risk management. The Board of Management of the Company is responsible for monitoring the risk management process to ensure the appropriate balance between risk and risk control.

Market risk

The Company's business operations will bear the risks of changes in exchange rates and interest rates.

Exchange rate risk

The Company bears the risk of interest rates due to the transaction made in a foreign currency other than VND such as: borrowings and debts, revenue, cost, importing materials, good, machinery and equipment.

Interest rate risk

The Company bears the risk of interest rates due to the fluctuation in fair value of future cash flow of a financial instrument in line with changes in market interest rates if the Company has time or demand deposits, borrowings and debts subject to floating interest rates. The Company manages interest rate risk by analyzing the market competition situation to obtain interest beneficial for its operation purpose.

Credit Risk

Credit risk is the risk of financial loss to the Company if a counterparty fails to perform its contractual obligations. The Company has credit risk from operating activities (mainly to trade receivables) and financial activities (including deposits, loans and other financial instruments), detailed as follows:

	Under 1 year VND	From 1 to 5 years VND	Over 5 years VND	Total VND
As at 30/06/2025				
Cash and cash equivalents	60,229,581,062	-	-	60,229,581,062
Trade and other receivables	323,276,305,184	3,542,051,820	-	326,818,357,004
Loans	-	-	-	-
	383,505,886,246	3,542,051,820	-	387,047,938,066
As at 01/01/2025				
Cash and cash equivalents	39,027,489,445	-	-	39,027,489,445
Trade and other receivables	297,406,733,959	3,576,969,012	-	300,983,702,971
Loans	5,000,000,000	-	-	5,000,000,000
	341,434,223,404	3,576,969,012	-	345,011,192,416

Liquidity Risk

Liquidity risk is the risk that the Company has trouble in settlement of its due date financial obligations due to the lack of funds. Liquidity risk of the Company mainly arises from different maturity of its financial assets and liabilities.

Due date for payment of financial liabilities based on expected payment under the contracts (based on cash flow of the original debts) as follows:

	Under 1 year VND	From 1 to 5 years VND	Over 5 years VND	Total VND
As at 30/06/2025				
Borrowings and debts	43,541,967,159	23,900,000,000	-	67,441,967,159
Trade and other payables	82,168,452,960	202,500,000	-	82,370,952,960
Accrued expenses	107,154,194	-	-	107,154,194
	125,817,574,313	24,102,500,000	-	149,920,074,313
As at 01/01/2025				
Borrowings and debts	41,694,687,517	30,450,000,000	-	72,144,687,517
Trade and other payables	91,238,538,362	131,500,000	-	91,370,038,362
Accrued expenses	1,013,834,994	-	-	1,013,834,994
	133,947,060,873	30,581,500,000	-	164,528,560,873

The Company believes that risk level of loan repayment is controllable. The Company has the ability to pay due debts from cash flows from its operating activities and cash received from mature financial assets.

34. ADDITIONAL INFORMATION FOR THE ITEMS OF THE STATEMENT OF CASH FLOWS

	From 01/01/2025 to 30/06/2025	From 01/01/2024 to 30/06/2024
	VND	VND
a) Proceeds from borrowings during the period		
Proceeds from ordinary contracts	38,802,468,654	57,126,042,081
b) Actual repayments on principal during the period		
Repayment on principal from ordinary contracts	43,505,189,012	58,209,089,281

35. SUBSEQUENT EVENTS AFTER THE REPORTING PERIOD

There have been no significant events occurring after the reporting period, which would require adjustments or disclosures to be made in the Interim Financial Statements.

36. TRANSACTION AND BALANCES WITH RELATED PARTIES

List and relation between related parties and the Company are as follows:

Related parties	Relation
Ms. Le Thi Kim Anh	Major shareholder and related person of the Key Management Member
Mr. Nguyen Tien Lung	Major shareholder and related person of the Key Management Member
Ms. Phung Thanh Huong	Major shareholder and related person of the Key Management Member
Medzavy Pharmaceutical Joint Stock Company	Mr. Le Nam Thang is the Chairman of the Board of Directors of the Company and the Director and Legal Representative of this Company
CPC1 Central Pharmaceutical Joint Stock Company	Mr. Nguyen Doan Liem is a Member of the Board of Directors of the Company and a Member of the Board of Directors of this Company
Tan Thinh Pharmaceutical Co., Ltd.	Mr. Nguyen Thanh Binh is a Member of the Board of Directors of the Company and is the Director and Legal Representative of this Company
VNP Pharmaceutical Co., Ltd.	Mr. Tran Nghia Loi is a Member of the Board of Directors of the Company and Director of this Company Mr. Nguyen Thanh Binh is a Member of the Board of Directors of the Company and Deputy Director of this Company
UPHARMA Joint Stock Company	Mr. Le Nam Thang is the Chairman of the Board of Directors of the Company and the Chairman of the Board of Directors and the Legal Representative of this Company. Mr. Nguyen Thanh Binh is a Member of the Board of Directors of the Company and a Member of the Board of Directors of this Company
UPHARMA Solutions and Technology Co., Ltd.	Mr. Nguyen Thanh Binh is a Director of the Company
The members of the Board of Directors, the Board of Management, the Board of Supervision	

In addition to the information with related parties presented in the above Notes. During the period, the Company has transactions with related parties as follows:

	From 01/01/2025 to 30/06/2025	From 01/01/2024 to 30/06/2024
	VND	VND
Revenue from sales and services	46,528,500,503	34,864,516,430
- CPC1 Central Pharmaceutical Joint Stock Company	48,359,940	152,381
- Tan Thinh Pharmaceutical Co., Ltd.	27,185,667,442	16,593,549,367
- VNP Pharmaceutical Co., Ltd.	16,051,024,279	16,297,970,872
- UPHARMA Joint Stock Company	3,243,448,842	1,963,543,190
- Medzavy Pharmaceutical Joint Stock Company	-	9,300,620
Returned sales	175,605,650	45,847,584
- VNP Pharmaceutical Co., Ltd.	-	45,847,584
- Tan Thinh Pharmaceutical Co.,	174,389,650	-
- UPHARMA Joint Stock Company	1,216,000	-
Purchase of goods and services	15,821,599,572	9,472,120,188
In which	15,821,599,572	9,472,120,188
<i>Purchase for production and purchase of goods</i>	<i>14,382,882,315</i>	<i>8,273,934,315</i>
<i>Selling expenses</i>	<i>661,117,257</i>	<i>407,266,220</i>
<i>Prepaid expenses</i>	<i>777,600,000</i>	<i>790,919,653</i>
- CPC1 Central Pharmaceutical	1,308,917,257	1,229,600,720
- Tan Thinh Pharmaceutical Co.,	14,174,925,428	8,181,919,468
- UPHARMA Joint Stock Company	207,956,887	-
- VNP Pharmaceutical Co., Ltd.	80,000,000	-
- Ms. Phung Thanh Huong	49,800,000	60,600,000
Other commitments		
- The savings deposit book in the name of Mr. Le Nam Thang, valued at VND 10,000,000 under the Pledge Contract No. NTL-HDCC/24031 is used as collateral for the unit's loan (detailed in Notes No. 14a).		

Remuneration of key management persons:

	From 01/01/2025 to 30/06/2025	From 01/01/2024 to 30/06/2024
Relation	VND	VND
- Mr. Le Nam Thang	411,008,334	555,833,334
- Mr. Nguyen Doan Liem	32,000,000	32,000,000
- Mr. Vu Van Ha	-	32,000,000
	(Term 2020-2024 expires on 05/04/2024)	
- Mr. Nguyen Thanh Binh	711,257,666	802,854,166
	Member of the Board of Directors General Director	
- Mr. Tran Nghia Loi	29,333,333	-
	Member of the Board of Directors (Appointed on 05/04/2024)	
- Mr. Tran Minh Thanh	236,248,334	359,368,334
	Deputy General Director	
- Ms. Dang Thi Thu Thuy	342,034,787	397,794,825
	Chief Accountant	
- Ms. Ta Thi Hai Huyen	163,001,666	263,305,000
	Persons authorized to disclose information	

	Relation	From 01/01/2025	From 01/01/2024
		to 30/06/2025	to 30/06/2024
		VND	VND
- Ms. Tran Thuy Khanh	Head of the Supervisory Board	156,975,000	177,000,000
- Ms. Tran Thi Phuong Thao	Member of the Supervisory Board (Term 2020-2024 expires on 05/04/2024)	-	198,237,191
- Ms. Truong Thi Hue	Member of the Supervisory Board (Term 2020-2024 expires on 05/04/2024)	-	12,000,000
- Ms. Ha Thi Mai	Members of the Supervisory Board	139,198,666	46,215,001
- Ms. Nguyen Thi Kim Oanh	Members of the Supervisory Board	258,448,534	192,358,000

In addition to the above related parties transactions, other related parties did not have any transactions during the period and have no balance at the end of the period with the Company.

37. COMPARATIVE FIGURES

The comparative figures on the Interim Statement of Financial Position and corresponding Notes are taken from the Financial Statements for the fiscal year ended as at 31 December 2024, which was audited by AASC Auditing Firm Company Limited. The comparative figures on the Interim Statement of Income, Interim Statement of Cash Flows, and corresponding Notes are taken from the Interim Financial Statements which have been reviewed for the period from 01/01/2024 to 30/06/2024.



Nguyen Thi Xuan Hoan
Preparer
Hanoi, 12 August 2025



Dang Thi Thu Thuy
Chief Accountant



Le Nam Thang
Chairman